{"commentary":{"count":12,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"podcast":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05050942\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"SORENTO","nct_id":"NCT05050942","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sorento-nct05050942. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"SORENTO","arms":[{"description":null,"label":"CAM2029","type":"EXPERIMENTAL"},{"description":null,"label":"Octreotide LAR or lanreotide ATG","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2028-11","type":"ESTIMATED"},"conditions":["Gastro-enteropancreatic Neuroendocrine Tumor"],"enrollment":{"count":332,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CAM2029","type":"DRUG"},{"name":"Octreotide LAR","type":"DRUG"},{"name":"Lanreotide ATG","type":"DRUG"}],"last_update":"2026-07-28","lead_sponsor":"Camurus AB","official_title":"A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2026-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)","timeFrame":"From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months"}],"references":[{"citation":"Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellstrom L, Liedman H, Svedberg A, Tiberg F. Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8.","pmid":"38229199","type":"DERIVED"}],"start_date":{"date":"2021-10-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","url":"https://clinicaltrials.gov/study/NCT05050942"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sorento-nct05050942"}